merck - Search News

Merck 2025 Sales Forecast Underwhelms

Bloomberg on MSN · 2h

Merck’s Gardasil Halt Shows Blockbuster Shots’ Dilemma in China

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US pharmaceutical giant made the call earlier this week to halt shipments.

Business Insider · 7h

Merck Stock Loses 9% on Vaccine Shipment Halt to China

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The pharmaceutical

The Associated Press - Busines… · 22h

Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

Merck beats estimates on fourth-quarter on earnings

Merck beats estimates on fourth-quarter on earnings—but stock slides pre-market on tepid 2025 guidance

Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its stock was down more than 8% in pre-market trading, largely because of weaker than expected 2025 guidance.

Seeking Alpha · 1d

Merck stock slides as 2025 earnings outlook misses estimates

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations with Keytruda sales.

MarketWatch on MSN · 1d

Merck’s soft guidance offsets better-than-expected fourth-quarter earnings

Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset better-than-expected fourth-quarter earnings. Rahway, N.J.-based Merck had per-share income of $1.

17hon MSN

Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

18h

Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential

Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

2hon MSN

Merck Is Suffering From a Classic Pharma Problem

Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.

50m

Merck price target lowered to $112 from $118 at BofA

BofA lowered the firm’s price target on Merck (MRK) to $112 from $118 and keeps a Buy rating on the shares. Q4 results were “decent,” but 2025 ...

18hon MSN

Why Merck Stock Is Plummeting Today

Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...

19h

Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

16hon MSN

These Stocks Are Moving the Most Today: Palantir, Alphabet, Tesla, Merck, PayPal, Super Micro, Spotify, Estée Lauder, and More

Palantir stock surges as artificial-intelligence gains drive an earnings and revenue beat, China begins an antitrust probe ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results